Maxim Comments On Sucampo Following Paragraph IV Certification Notice
In a research report released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Sucampo (NASDAQ:SCMP) with a $15 price target, as the company received a paragraph IV certification notice letter regarding an ANDA submitted to the FDA by Par Pharmaceutical, requesting approval to market, sell, and use a generic version of SCMP’s Rescula.
Kolbert said, “We do not include any Rescula revenues in our income statement as the company has not been focusing on the product. As such, a generic form of rescula is not a factor for the company. He added, “Our focus remains on Amitiza. We believe the company is now thinking about product acquisition opportunities too.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 1.1% and a 38.0% success rate. Kolbert has an 26.1% average return when recommending SCMP, and is ranked #1653 out of 3426 analysts.